Insider Selling: Abbott Laboratories (ABT) SVP Sells 996 Shares of Stock
Abbott Laboratories (NYSE:ABT) SVP Jared Watkin sold 996 shares of the stock in a transaction dated Thursday, March 1st. The stock was sold at an average price of $58.87, for a total value of $58,634.52. Following the transaction, the senior vice president now owns 69,511 shares of the company’s stock, valued at $4,092,112.57. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Jared Watkin also recently made the following trade(s):
- On Tuesday, February 20th, Jared Watkin sold 297 shares of Abbott Laboratories stock. The stock was sold at an average price of $59.29, for a total value of $17,609.13.
Shares of Abbott Laboratories (ABT) traded up $0.67 during midday trading on Friday, hitting $59.46. The stock had a trading volume of 7,692,487 shares, compared to its average volume of 8,020,000. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.26 and a quick ratio of 1.86. Abbott Laboratories has a one year low of $42.31 and a one year high of $64.60. The company has a market cap of $103,500.00, a P/E ratio of 57.17, a P/E/G ratio of 1.77 and a beta of 1.52.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, May 15th. Stockholders of record on Friday, April 13th will be paid a dividend of $0.28 per share. The ex-dividend date of this dividend is Thursday, April 12th. This represents a $1.12 annualized dividend and a dividend yield of 1.88%. Abbott Laboratories’s dividend payout ratio is currently 107.69%.
A number of research analysts recently issued reports on ABT shares. Bank of America increased their price objective on Abbott Laboratories from $60.00 to $70.00 in a report on Wednesday, January 24th. They noted that the move was a valuation call. Royal Bank of Canada reiterated a “buy” rating and set a $65.00 price objective on shares of Abbott Laboratories in a report on Tuesday, January 9th. Barclays restated a “buy” rating and issued a $66.00 price target on shares of Abbott Laboratories in a research note on Monday, January 8th. Zacks Investment Research upgraded Abbott Laboratories from a “hold” rating to a “buy” rating and set a $64.00 price target for the company in a research note on Tuesday, January 2nd. Finally, ValuEngine upgraded Abbott Laboratories from a “hold” rating to a “buy” rating in a research note on Wednesday, November 22nd. Seven research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $65.47.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Gratus Capital LLC lifted its holdings in Abbott Laboratories by 0.9% during the 2nd quarter. Gratus Capital LLC now owns 205,067 shares of the healthcare product maker’s stock worth $9,968,000 after purchasing an additional 1,869 shares during the last quarter. Moody Lynn & Lieberson LLC lifted its holdings in Abbott Laboratories by 17.1% during the 3rd quarter. Moody Lynn & Lieberson LLC now owns 326,468 shares of the healthcare product maker’s stock worth $17,420,000 after purchasing an additional 47,610 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in Abbott Laboratories during the 3rd quarter worth approximately $47,713,000. Vantage Investment Advisors LLC lifted its holdings in Abbott Laboratories by 103.4% during the 2nd quarter. Vantage Investment Advisors LLC now owns 72,161 shares of the healthcare product maker’s stock worth $3,508,000 after purchasing an additional 36,683 shares during the last quarter. Finally, Brightworth acquired a new stake in Abbott Laboratories during the 3rd quarter worth approximately $841,000. Institutional investors own 70.01% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This article was first posted by Watch List News and is owned by of Watch List News. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.watchlistnews.com/insider-selling-abbott-laboratories-abt-svp-sells-996-shares-of-stock/1905140.html.
About Abbott Laboratories
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.